02 Mar 2021

CRUK teams up with Teon to trial first-in-class cancer drug

Cancer Research UK (CRUK) has signed a clinical development collaboration with California-based Teon Therapeutics. Teon’s work focuses on developing a portfolio of immunotherapies for cancer that modulates and antagonises metabolic…

26 Feb 2021

Merck signs agreement to buy Pandion Therapeutics for $1.85bn

Merck has agreed to acquire biotechnology company Pandion Therapeutics for approximately $1.85bn to expand its portfolio of autoimmune disease-targeting candidates. Under the agreement, Merck will initiate a tender offer through…